SC14D9C

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14D-9

(Rule 14d-101)

Solicitation/Recommendation Statement

Under Section 14(d)(4) of the Securities Exchange Act of 1934

LDR HOLDING CORPORATION

(Name of Subject Company)

LDR HOLDING CORPORATION

(Name of Persons Filing Statement)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

50185U105

(CUSIP Number of Class of Securities)

Scott Way

Executive Vice President and General Counsel

LDR Holding Corporation

13785 Research Boulevard, Suite 200

Austin, Texas 78750

(512) 344-3333

(Name, address and telephone numbers of person authorized to receive notice and communications

on behalf of the persons filing statement)

With copies to:

Carmelo M. Gordian

J. Russel Denton

Andrews Kurth LLP

111 Congress Avenue, Suite 1700

Austin, Texas 78701

(512) 320-9200

þ Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

This Schedule 14D-9 filing consists of the communications listed below related to the proposed acquisition of LDR Holding Corporation, a Delaware corporation (the “LDR”) by LH Merger Sub, Inc., a Delaware corporation (“Merger Sub”), and an indirect wholly owned subsidiary of Zimmer Biomet Holdings, Inc. (“Zimmer Biomet”), a Delaware corporation, pursuant to the Agreement and Plan of Merger, dated as of June 6, 2016, by among LDR, Merger Sub and Zimmer Biomet.

• Exhibit 99.1 Form of Letter to Employees

• Exhibit 99.2 Employee Frequently Asked Questions

• Exhibit 99.3 Form of Surgeon Customer Letter

• Exhibit 99.4 Form of Product Designer or Consultant Letter

• Exhibit 99.5 Joint Press Release, dated June 7, 2016, of Zimmer Biomet Holdings, Inc. and LDR Holding Corporation

• Exhibit 99.6 Investor Deck of Zimmer Biomet Holdings, Inc.

EX-99.1

Exhibit 99.1

To all LDR employees,

I am excited to announce that the LDR Board of Directors has accepted an offer from Zimmer Biomet to acquire LDR. Zimmer Biomet is a global leader in musculoskeletal healthcare committed to helping people live better lives. Zimmer Biomet will acquire all of the outstanding shares of LDR common stock for $37.00 per share in cash, which implies a transaction value of $1.1 billion. This transaction is expected to close in Q3 of this year, subject to the satisfaction of customary closing conditions. Upon consummation of the transaction, all equity awards, including any stock options and restricted stock units, that you may have will accelerate and vest in full.

Since 2000, LDR has been passionate about delivering innovative technologies to improve the care for spine patients around the world. The Executive Team and I are excited about the planned combination of the LDR and Zimmer Biomet spine businesses as we anticipate it will dramatically increase access to the innovative LDR technologies worldwide. The combination will create a spine company with the scale, talent and technology portfolio to become a leader in the $10 billion global spine market. The combined company will be increasingly competitively positioned in the fast growing cervical disc replacement market.

Regarding next steps, LDR and Zimmer Biomet Spine will remain separate companies and operate independently until the transaction is consummated. So it is “business as usual” for LDR. There will be some initial integration planning activities over the next several weeks and we will keep you informed of any developments.

As you all know, LDR is one of my “babies.” I have seen us grow and develop to become one of the best success stories in the orthopaedic industry. This success is your success, and you should be as proud as I am to have provided to thousands of people a better life after spine surgery. Tomorrow, it is not thousands of people who will benefit from our technology but millions of people who will benefit around the globe. This next step for our company is an exciting time, and Patrick Richard and I are excited to be able to continue to support the combined company following the transaction.

Please see the attached Frequently Asked Questions (FAQ) document and also a letter to LDR employees from Adam Johnson, Zimmer Biomet Group President for Spine, Dental, CMF and Thoracic. In addition, we will be holding company meetings today to provide more information on this exciting opportunity.

We are looking forward to working with the Zimmer Biomet team to capture the significant growth opportunities this combination creates, and I would like to thank all of you for your commitment, hard work and loyalty.

Christophe Lavigne

President & CEO

1

Cautionary Statement Regarding Forward-Looking Statements

This communication contains forward-looking information related to Zimmer Biomet, LDR and the acquisition of LDR by Zimmer Biomet that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. All statements other than statements of historical fact are, or may be deemed to be, forward-looking statements. In some cases, forward-looking statements can be identified by the use of forward-looking terms such as “anticipate,” “estimate,” “believe,” “continue,” “could,” “intend,” “may,” “plan,” “potential,” “predict,” “should,” “will,” “expect,” “objective,” “projection,” “forecast,” “goal,” “guidance,” “outlook,” “effort,” “target”, “would” or the negative of these terms or other comparable terms. Forward-looking statements in this communication include, among other things, statements about the potential benefits of the proposed acquisition; anticipated accretion and growth rates; Zimmer Biomet’s and LDR’s plans, objectives, expectations and intentions; the financial condition, results of operations and businesses of Zimmer Biomet and LDR; and the anticipated timing of closing of the acquisition. These forward-looking statements are based on certain assumptions and analyses made by us in light of our experience and our perception of historical trends, current conditions and expected future developments, as well as other factors we believe are appropriate in the circumstances. These forward-looking statements also are based on the current expectations and beliefs of the respective managements of Zimmer Biomet and LDR and are subject to certain known and unknown risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Risks and uncertainties include, among other things, risks related to the satisfaction of the conditions to closing the acquisition (including the failure to obtain necessary regulatory approvals) in the anticipated timeframe or at all, including uncertainties as to how many of LDR’s stockholders will tender their shares of LDR common stock in the tender offer and the possibility that the acquisition does not close; risks related to the ability to realize the anticipated benefits of the acquisition, including the possibility that the expected benefits from the proposed acquisition will not be realized or will not be realized within the expected time period; the risk that the businesses will not be integrated successfully; disruption from the transaction making it more difficult to maintain business and operational relationships; negative effects of this announcement or the consummation of the proposed acquisition on the market price of Zimmer Biomet common stock and on Zimmer Biomet’s operating results; significant transaction costs; unknown liabilities; the risk of litigation and/or regulatory actions related to the proposed acquisition; other business effects, including the effects of industry, market, economic, political or regulatory conditions; future exchange rates and interest rates; changes in tax and other laws, regulations and policies; future business combinations or disposals; the uncertainties inherent in research and development; and competitive developments. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Zimmer Biomet and LDR undertake no obligation to update any of these forward-looking statements as the result of new information or to reflect events or circumstances after the date of this communication or to reflect actual outcomes. A further description of risks and uncertainties relating to Zimmer Biomet and LDR can be found in their respective Annual Reports on Form 10-K for the fiscal year ended December 31, 2015 and

2

in their subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission (the “SEC”) and available at www.sec.gov.

Additional Information and Where to Find It

The tender offer referenced in this communication has not yet commenced. This announcement is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell any shares of LDR common stock or any other securities, nor is it a substitute for the tender offer materials that Zimmer Biomet and its indirect subsidiary, LH Merger Sub, Inc., will file with the SEC. The solicitation and offer to purchase LDR common stock will only be made pursuant to an Offer to Purchase, a related letter of transmittal and certain other tender offer documents. At the time the tender offer is commenced, Zimmer Biomet and LH Merger Sub will file a tender offer statement on Schedule TO, including an Offer to Purchase, a related letter of transmittal and certain other tender offer documents, and LDR will file a Solicitation/Recommendation Statement on Schedule 14D-9, with the SEC, each with respect to the tender offer. THE TENDER OFFER STATEMENT (INCLUDING THE OFFER TO PURCHASE, THE RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER TENDER OFFER DOCUMENTS) AND THE SOLICITATION/RECOMMENDATION STATEMENT WILL CONTAIN IMPORTANT INFORMATION. LDR STOCKHOLDERS ARE URGED TO READ THE TENDER OFFER STATEMENT AND SOLICITATION/ RECOMMENDATION STATEMENT, AS THEY MAY BE AMENDED FROM TIME TO TIME, AS WELL AS ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC, WHEN THEY BECOME AVAILABLE, CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION THAT HOLDERS OF LDR SECURITIES SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING TENDERING THEIR SECURITIES. The Offer to Purchase, the related Letter of Transmittal and certain other tender offer documents, as well as the Solicitation/Recommendation Statement, will be made available to all holders of LDR common stock at no expense to them. The tender offer materials and the Solicitation/Recommendation Statement will be made available for free at the SEC’s website at www.sec.gov. Additional copies may be obtained (when available) for free by contacting Zimmer Biomet or LDR. Copies of the documents filed with the SEC by LDR will be available free of charge on LDR’s website at www.ldr.com or by contacting LDR’s Investor Relations Department at (512) 344-3408. Copies of the documents filed with the SEC by Zimmer Biomet will be available free of charge on Zimmer Biomet’s website at www.zimmerbiomet.com or by contacting Zimmer Biomet’s Investor Relations Department at (574) 267-6131. In addition to the Offer to Purchase, the related Letter of Transmittal and certain other tender offer documents, as well as the Solicitation/Recommendation Statement, Zimmer Biomet and LDR each file annual, quarterly and current reports and other information with the SEC. You may read and copy any reports or other information filed by Zimmer Biomet or LDR at the SEC public reference room at 100 F Street, N.E., Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for further information on the public reference room. Zimmer Biomet’s and LDR’s filings with the SEC are also available to the public from commercial document-retrieval services and at the website maintained by the SEC at www.sec.gov.

Biomet or LDR. Copies of the documents filed with the SEC by LDR will be available free of charge on LDR’s website at www.ldr.com or by contacting LDR’s Investor Relations Department at (512) 344-3408. Copies of the documents filed with the SEC by Zimmer Biomet will be available free of charge on Zimmer Biomet’s website at www.zimmerbiomet.com or by contacting Zimmer Biomet’s Investor Relations Department at (574) 267-6131. In addition to the Offer to Purchase, the related Letter of Transmittal and certain other tender offer documents, as well as the Solicitation/Recommendation Statement,

3

Zimmer Biomet and LDR each file annual, quarterly and current reports and other information with the SEC. You may read and copy any reports or other information filed by Zimmer Biomet or LDR at the SEC public reference room at 100 F Street, N.E., Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for further information on the public reference room. Zimmer Biomet’s and LDR’s filings with the SEC are also available to the public from commercial document-retrieval services and at the website maintained by the SEC at www.sec.gov.

4

EX-99.2

Exhibit 99.2

LDR Employee FAQ

1. What was announced today?

• We announced that our Board of Directors has approved a Merger Agreement with Zimmer Biomet under which Zimmer Biomet will commence a tender offer to acquire all of the outstanding shares of LDR for $37.00 per share in cash, which implies a transaction value of approximately $1.1 billion. This transaction will combine the innovative technologies of our two companies, which is expected to bolster our combined scale, talent and technology portfolio and position Zimmer Biomet to become a leader in the $10 billion global spine market. We believe that the combination will deliver long-term value to healthcare providers and their patients. Importantly, the transaction will, with our Mobi-C^® technology, position Zimmer Biomet to capitalize on the fast growing cervical disc replacement segment.

• Together, we will be well-positioned for growth and will have one of the most comprehensive portfolios of spine technology in the industry. As a result of our complete suite of offerings, we will be better able to partner with surgeons across a broad spectrum of patient care.

2. What does today’s announcement mean for me?

• LDR will become part of a larger, more diverse company and we will be able to accelerate our growth strategy to better serve patients.

• The transaction is an important affirmation of our surgical solutions, and the hard work and dedication of you, our team.

• In the near term, today’s announcement should not change anything day-to-day.

• We have a phenomenal team at LDR that has a lot to offer the combined organization, and we expect that there will be meaningful opportunities to do so. As you can surely understand, it will take some time to decide on a specific integration plan.

• We understand that change of this magnitude can be challenging but please be assured that the fair treatment of our employees is very important to us.

• Until the transaction is consummated, LDR and Zimmer Biomet will continue to operate as separate companies and it is business as usual for LDR employees.

• It is important that you continue to concentrate on your daily activities and remain focused on our commitment to patients.

• We will keep you informed of key developments as we move forward.

3. When is the transaction expected to close?

The transaction is expected to close in the third quarter of 2016, subject to the satisfaction of customary closing conditions. Until then, we remain an independent company and it is business as usual for LDR.

1

4. Who is Zimmer Biomet?

• Founded in 1927 and headquartered in Warsaw, Indiana, Zimmer Biomet is a global leader in musculoskeletal healthcare. The spinal implant division of Zimmer Biomet is currently headquartered in Broomfield, Colorado.

• Zimmer Biomet designs, manufactures and markets orthopaedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants; and related surgical products.

• Zimmer Biomet collaborates with healthcare professionals around the globe to advance the pace of innovation. Their products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. Together with healthcare professionals, they help millions of people live better lives.

• They have operations in more than 25 countries around the world and sell products in more than 100 countries.

• For more information, visit www.zimmerbiomet.com.

5. Why does this combination create greater value?

• The combined entity will benefit from having a comprehensive portfolio of innovative spine solutions, creating a best-in-class cervical and thorocolumbar portfolio. The combination with Zimmer Biomet will allow for further growth of LDR’s market-leading CDR portfolio, and through Zimmer Biomet’s existing sales channels, expand LDR’s global distribution network.

6. After the transaction closes, where will the combined Spine business be headquartered? What will it be called? Who will lead it?

• Upon closing, LDR will be integrated into Zimmer Biomet’s Spine & CMF (cranial maxillofacial) segment and will be led by Adam Johnson, Zimmer Biomet Group President, Spine, Dental, CMF and Thoracic.

• Christophe Lavigne, Chairman, President and CEO of LDR, and Patrick Richard, Executive Vice President and General Manager of LDR Médical, will remain with the Company in key leadership positions within Zimmer Biomet’s global Spine business.

• To leverage talent and product expertise from both companies, Zimmer Biomet intends to complement its Spine headquarters in Broomfield, Colorado by also maintaining a significant presence in Austin, Texas and Troyes, France. The integration planning process will commence in the coming weeks. We will keep you informed throughout the process.

• It is important to remember that it is business as usual for LDR until the transaction closes and that, until the closing, LDR and Zimmer Biomet remain separate companies.

2

7. What happens to my LDR equity (stock options, restricted stock units or performance-based restricted stock units)?

• Upon consummation of the transaction, any LDR stock options (vested or unvested) will be converted into the right to receive $37.00 minus the exercise price per share for each share underlying an option (for example, if you have a stock option to acquire 100 shares at an exercise price of $27.00 per share, such stock option would be converted into the right to receive $1,000.00, less any required tax withholding). Options with an exercise price per share that is greater than $37.00 will be cancelled.

• Upon consummation of the transaction, each restricted stock unit (vested or unvested) will be converted into the right to receive $37.00 per share in cash (for example, 100 restricted stock units will be converted into the right to receive $3,700.00, less any required tax withholding).

• Upon consummation of the transaction, each earned performance-based restricted stock unit (vested or unvested) will be converted into the right to receive $37.00 per share in cash (for example, 100 performance-based restricted stock units will be converted into the right to receive $3,700.00, less any required tax withholding). The number of units earned will be adjusted as a result of the change-in-control of the Company as set forth in each performance-based restricted stock unit agreement.

8. What happens to shares purchased through the ESPP?

• ESPP shares that have already been purchased are treated in the same manner as all other outstanding shares and may be tendered into Zimmer Biomet offer to receive the $37.00 consideration (and, if such shares are not tendered into the tender offer, you will receive $37.00 per share upon the closing of the transaction).

• The Purchase Period for the ESPP that started on June 1, 2016 will have an expiration date prior to consummation of the transaction, and you will be able to make additional purchases under the ESPP in accordance with your current contributions.

• Employees may not increase their current contributions to the ESPP. Employees not currently enrolled in an ESPP are not eligible to join the program at this time.

9. Can I trade in LDR or Zimmer Biomet stock during open periods prior to the closing of the transaction?

• Yes; however, trading in LDR stock will continue to be subject to our Insider Trading Policy and applicable law.

• Any LDR employees that have material non-public information regarding the transaction, LDR or Zimmer Biomet, should refrain from trading in LDR or Zimmer Biomet stock.

10. What can you expect in the interim?

• We expect that today’s announcement will have no impact on day-to-day operations. Until the transaction is completed, it will be business as usual for LDR.

3

• In the coming days, we will be forming teams to assist with the planning and execution of our integration.

• We will continue to communicate developments regarding the transaction as we move through the process.

11. What are plans to integrate the two companies?

• Both companies have talented teams and a similar history and culture of excellence. While it is premature to discuss specifics, in the coming days we are establishing an integration-planning team that will begin working to address how we can best utilize each other’s strengths and bring our companies together.

• LDR and Zimmer Biomet have been focused in different segments of the spine market and each of these segments requires specific knowledge and experience.

• The combination of these businesses will only reach its potential if both teams are committed to our success, and we know we can count on your continued dedication.

12. What happens to LDR employees?

• This is a transaction about growth. While it’s premature to speculate about those specifics now, both companies recognize the importance of a strong sales team and skilled employees, and we will take the appropriate steps to ensure that our Customers continue to receive the superior levels of service that they have come to expect from both of our companies.

• LDR and Zimmer Biomet Spine have been focused in different segments of the spine market and each of these segments requires specific knowledge and experience.

• The combination of these businesses will only reach its potential if both teams are committed to our success, and we know we can count on your continued dedication.

• This combination will create a Company with the scale, talent and technology portfolio to become a leader in the $10 billion global spine market.

13. Will there be any layoffs as a result of the transaction?

• We have a phenomenal team at LDR that has a lot to offer the combined organization and we expect that there will be meaningful opportunities to do so.

• In the course of the integration-planning work, decisions will be made concerning organizational structure and design for the combined company. As decisions are made, we will continue to communicate with you.

• Overall, we expect there will be exciting opportunities for employees and sales representatives of both companies as part of a larger, more diversified organization.

• This transaction is about growth and expanding our offering to our Customers. Our businesses are highly complementary and there are strong teams at both companies.

• Zimmer Biomet is committed to treating all employees fairly throughout the integration process.

4

14. Should LDR employees expect any changes to benefits and compensation?

• Until the transaction closes, we will remain an independent company and there will be no changes to benefits and compensation plans.

• Following the closing, Zimmer Biomet has committed to providing substantially comparable benefits (excluding equity compensation benefits) to those provided by LDR until December 31, 2016.

• Following the closing, Zimmer Biomet has committed to providing the same base salary or wage rate and annual bonus opportunities as are provided as of the date of the Merger Agreement until December 31, 2016.

• Over the coming weeks, we will work with Zimmer Biomet to schedule meetings with you to discuss benefits that will be available to you starting in 2017.

• Zimmer Biomet is committed to treating all employees fairly throughout the integration process.

15. Will there be new opportunities in terms of jobs and relocation? Will I be asked to relocate? Will I have the opportunity to relocate?

• To leverage talent and product expertise from both companies, Zimmer Biomet intends to complement the Spine business headquarters in Broomfield, Colorado by also maintaining a significant presence in Austin, TX and Troyes, France.

• It is important to note that while today’s announcement is an important step, there are many decisions left to be made.

• Both LDR and Zimmer Biomet have proven organizations of talented and experienced employees and sales representatives with strong Customer relationships. We expect there will be exciting opportunities for employees and sales representatives of both companies as part of a larger, more diversified organization.

• Together, we believe that we will have the scale and resources to become a much stronger leader in spine technology.

16. How will the transaction affect our relationship with surgeons, providers and patients?

• Prior to the closing of the transaction, our Customers will experience no changes in their interactions with our LDR team. We expect a seamless transition for all of our healthcare stakeholders after the transaction closes.

• Among the many benefits for healthcare providers, the combined company’s innovative product portfolio is expected to enhance patient outcomes and enable us to partner with surgeons across a broad spectrum of spine patient care.

• As part of the integration process, we will be evaluating the best ways to leverage the combined strengths of LDR and Zimmer Biomet to meet the needs of the fast growing cervical disc replacement segment.

5

17. How will the transaction affect our relationship with our suppliers?

• Again, it is business as usual for LDR, and our suppliers will experience no changes in their interactions with us prior to the closing of the transaction. We expect a seamless transition for all of our healthcare stakeholders after the transaction closes.

• We value our relationship with our suppliers. As part of the integration process, we will be evaluating the best ways to leverage the combined organization.

18. What do I do if I’m asked about the transaction?

• We expect that today’s announcement will lead to increased interest in LDR from the media and our investors, and it is extremely important that we speak with one voice on this matter.

• Consistent with our company policy, please forward any media inquiries to Joe Ross at Joe.Ross@ldrspine.com or (512) 344-3410. Investor inquiries should be forwarded to Matt Norman at Matt.Norman@ldrspine.com or (512) 344-3408.

19. Where can employees obtain additional information?

• We will make every effort to ensure that you are informed about developments as they occur throughout this process.

• Many decisions still have to be made during the integration process, so answers to all of your questions may not be available until further along in the process.

• If you have additional questions or need guidance on matters not addressed through these FAQs or during later information updates, please send an email to hrquestion@ldrspine.com. We will be consolidating questions and will provide another communication in the near future.

6

Cautionary Statement Regarding Forward-Looking Statements

This communication contains forward-looking information related to Zimmer Biomet, LDR and the acquisition of LDR by Zimmer Biomet that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. All statements other than statements of historical fact are, or may be deemed to be, forward-looking statements. In some cases, forward-looking statements can be identified by the use of forward-looking terms such as “anticipate,” “estimate,” “believe,” “continue,” “could,” “intend,” “may,” “plan,” “potential,” “predict,” “should,” “will,” “expect,” “objective,” “projection,” “forecast,” “goal,” “guidance,” “outlook,” “effort,” “target”, “would” or the negative of these terms or other comparable terms. Forward-looking statements in this communication include, among other things, statements about the potential benefits of the proposed acquisition; anticipated accretion and growth rates; Zimmer Biomet’s and LDR’s plans, objectives, expectations and intentions; the financial condition, results of operations and businesses of Zimmer Biomet and LDR; and the anticipated timing of closing of the acquisition. These forward-looking statements are based on certain assumptions and analyses made by us in light of our experience and our perception of historical trends, current conditions and expected future developments, as well as other factors we believe are appropriate in the circumstances. These forward-looking statements also are based on the current expectations and beliefs of the respective managements of Zimmer Biomet and LDR and are subject to certain known and unknown risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Risks and uncertainties include, among other things, risks related to the satisfaction of the conditions to closing the acquisition (including the failure to obtain necessary regulatory approvals) in the anticipated timeframe or at all, including uncertainties as to how many of LDR’s stockholders will tender their shares of LDR common stock in the tender offer and the possibility that the acquisition does not close; risks related to the ability to realize the anticipated benefits of the acquisition, including the possibility that the expected benefits from the proposed acquisition will not be realized or will not be realized within the expected time period; the risk that the businesses will not be integrated successfully; disruption from the transaction making it more difficult to maintain business and operational relationships; negative effects of this announcement or the consummation of the proposed acquisition on the market price of Zimmer Biomet common stock and on Zimmer Biomet’s operating results; significant transaction costs; unknown liabilities; the risk of litigation and/or regulatory actions related to the proposed acquisition; other business effects, including the effects of industry, market, economic, political or regulatory conditions; future exchange rates and interest rates; changes in tax and other laws, regulations and policies; future business combinations or disposals; the uncertainties inherent in research and development; and competitive developments. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Zimmer Biomet and LDR undertake no obligation to update any of these forward-looking

7

statements as the result of new information or to reflect events or circumstances after the date of this communication or to reflect actual outcomes. A further description of risks and uncertainties relating to Zimmer Biomet and LDR can be found in their respective Annual Reports on Form 10-K for the fiscal year ended December 31, 2015 and in their subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission (the “SEC”) and available at www.sec.gov.

Additional Information and Where to Find It

The tender offer referenced in this communication has not yet commenced. This announcement is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell any shares of LDR common stock or any other securities, nor is it a substitute for the tender offer materials that Zimmer Biomet and its indirect subsidiary, LH Merger Sub, Inc., will file with the SEC. The solicitation and offer to purchase LDR common stock will only be made pursuant to an Offer to Purchase, a related letter of transmittal and certain other tender offer documents. At the time the tender offer is commenced, Zimmer Biomet and LH Merger Sub will file a tender offer statement on Schedule TO, including an Offer to Purchase, a related letter of transmittal and certain other tender offer documents, and LDR will file a Solicitation/Recommendation Statement on Schedule 14D-9, with the SEC, each with respect to the tender offer. THE TENDER OFFER STATEMENT (INCLUDING THE OFFER TO PURCHASE, THE RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER TENDER OFFER DOCUMENTS) AND THE SOLICITATION/RECOMMENDATION STATEMENT WILL CONTAIN IMPORTANT INFORMATION. LDR STOCKHOLDERS ARE URGED TO READ THE TENDER OFFER STATEMENT AND SOLICITATION/ RECOMMENDATION STATEMENT, AS THEY MAY BE AMENDED FROM TIME TO TIME, AS WELL AS ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC, WHEN THEY BECOME AVAILABLE, CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION THAT HOLDERS OF LDR SECURITIES SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING TENDERING THEIR SECURITIES. The Offer to Purchase, the related Letter of Transmittal and certain other tender offer documents, as well as the Solicitation/Recommendation Statement, will be made available to all holders of LDR common stock at no expense to them. The tender offer materials and the Solicitation/Recommendation Statement will be made available for free at the SEC’s website at www.sec.gov. Additional copies may be obtained (when available) for free by contacting Zimmer Biomet or LDR. Copies of the documents filed with the SEC by LDR will be available free of charge on LDR’s website at www.ldr.com or by contacting LDR’s Investor Relations Department at (512) 344-3408. Copies of the documents filed with the SEC by Zimmer Biomet will be available free of charge on Zimmer Biomet’s website at www.zimmerbiomet.com or by contacting Zimmer Biomet’s Investor Relations Department at (574) 267-6131. In addition to the Offer to Purchase, the

8

related Letter of Transmittal and certain other tender offer documents, as well as the Solicitation/Recommendation Statement, Zimmer Biomet and LDR each file annual, quarterly and current reports and other information with the SEC. You may read and copy any reports or other information filed by Zimmer Biomet or LDR at the SEC public reference room at 100 F Street, N.E., Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for further information on the public reference room. Zimmer Biomet’s and LDR’s filings with the SEC are also available to the public from commercial document-retrieval services and at the website maintained by the SEC at www.sec.gov.

9

EX-99.3

Exhibit 99.3

June 7, 2016

Dear Valued LDR Customer,

Today is an exciting day for LDR. This morning, it was announced that Zimmer Biomet will be acquiring LDR and merging it with its existing spine business. The transaction is expected to close in the third quarter of 2016, subject to the satisfaction of customary closing conditions. Until then, LDR and Zimmer Biomet will remain independent companies and it will be business as usual.

As you may know, Zimmer Biomet is a global leader in musculoskeletal healthcare committed to helping people live better lives. This transaction will combine LDR’s innovative and highly differentiated products with the broad portfolio of spinal solutions offered by Zimmer Biomet.

The benefits for you are clear. Following the close of the transaction, the combined company will have a comprehensive Spinal technology portfolio consisting of differentiated fusion and market-leading non-fusion devices that will enable us to partner with you across a broad spectrum of patient care. The combined business will maintain an expansive global distribution channel that consists of a hybrid network of direct and independent distributors in both the US and key international markets. In turn, we expect that you will enjoy complete access to an unparalleled portfolio of technologies through the LDR and Zimmer Biomet sales professionals you already know and trust.

We believe that the combination will create a spine company with scale, talent and the technology portfolio to become a leader in the global spine market and continue to be the partner of choice for surgeons who are creating the spine technologies of the future.

Please continue to engage with your usual points of contact in the normal course of business, and feel free to reach out to your LDR representative with any questions. We will continue to deliver the same level of service and support that you have come to appreciate from LDR.

Our relationship with you is important to our continued success. We appreciate your business, loyalty and support, and are excited about this opportunity to deepen our ability to serve you in our combined efforts to positively change the lives of your patients.

Best regards,

Christophe Lavigne

President and CEO

LDR

1

Cautionary Statement Regarding Forward-Looking Statements

This communication contains forward-looking information related to Zimmer Biomet, LDR and the acquisition of LDR by Zimmer Biomet that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. All statements other than statements of historical fact are, or may be deemed to be, forward-looking statements. In some cases, forward-looking statements can be identified by the use of forward-looking terms such as “anticipate,” “estimate,” “believe,” “continue,” “could,” “intend,” “may,” “plan,” “potential,” “predict,” “should,” “will,” “expect,” “objective,” “projection,” “forecast,” “goal,” “guidance,” “outlook,” “effort,” “target”, “would” or the negative of these terms or other comparable terms. Forward-looking statements in this communication include, among other things, statements about the potential benefits of the proposed acquisition; anticipated accretion and growth rates; Zimmer Biomet’s and LDR’s plans, objectives, expectations and intentions; the financial condition, results of operations and businesses of Zimmer Biomet and LDR; and the anticipated timing of closing of the acquisition. These forward-looking statements are based on certain assumptions and analyses made by us in light of our experience and our perception of historical trends, current conditions and expected future developments, as well as other factors we believe are appropriate in the circumstances. These forward-looking statements also are based on the current expectations and beliefs of the respective managements of Zimmer Biomet and LDR and are subject to certain known and unknown risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Risks and uncertainties include, among other things, risks related to the satisfaction of the conditions to closing the acquisition (including the failure to obtain necessary regulatory approvals) in the anticipated timeframe or at all, including uncertainties as to how many of LDR’s stockholders will tender their shares of LDR common stock in the tender offer and the possibility that the acquisition does not close; risks related to the ability to realize the anticipated benefits of the acquisition, including the possibility that the expected benefits from the proposed acquisition will not be realized or will not be realized within the expected time period; the risk that the businesses will not be integrated successfully; disruption from the transaction making it more difficult to maintain business and operational relationships; negative effects of this announcement or the consummation of the proposed acquisition on the market price of Zimmer Biomet common stock and on Zimmer Biomet’s operating results; significant transaction costs; unknown liabilities; the risk of litigation and/or regulatory actions related to the proposed acquisition; other business effects, including the effects of industry, market, economic, political or regulatory conditions; future exchange rates and interest rates; changes in tax and other laws, regulations and policies; future business combinations or disposals; the uncertainties inherent in research and development; and competitive developments. Readers are cautioned not to place undue reliance on any of these

2

forward-looking statements. These forward-looking statements speak only as of the date hereof. Zimmer Biomet and LDR undertake no obligation to update any of these forward-looking statements as the result of new information or to reflect events or circumstances after the date of this communication or to reflect actual outcomes. A further description of risks and uncertainties relating to Zimmer Biomet and LDR can be found in their respective Annual Reports on Form 10-K for the fiscal year ended December 31, 2015 and in their subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission (the “SEC”) and available at www.sec.gov.

Additional Information and Where to Find It

The tender offer referenced in this communication has not yet commenced. This announcement is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell any shares of LDR common stock or any other securities, nor is it a substitute for the tender offer materials that Zimmer Biomet and its indirect subsidiary, LH Merger Sub, Inc., will file with the SEC. The solicitation and offer to purchase LDR common stock will only be made pursuant to an Offer to Purchase, a related letter of transmittal and certain other tender offer documents. At the time the tender offer is commenced, Zimmer Biomet and LH Merger Sub will file a tender offer statement on Schedule TO, including an Offer to Purchase, a related letter of transmittal and certain other tender offer documents, and LDR will file a Solicitation/Recommendation Statement on Schedule 14D-9, with the SEC, each with respect to the tender offer. THE TENDER OFFER STATEMENT (INCLUDING THE OFFER TO PURCHASE, THE RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER TENDER OFFER DOCUMENTS) AND THE SOLICITATION/RECOMMENDATION STATEMENT WILL CONTAIN IMPORTANT INFORMATION. LDR STOCKHOLDERS ARE URGED TO READ THE TENDER OFFER STATEMENT AND SOLICITATION/ RECOMMENDATION STATEMENT, AS THEY MAY BE AMENDED FROM TIME TO TIME, AS WELL AS ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC, WHEN THEY BECOME AVAILABLE, CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION THAT HOLDERS OF LDR SECURITIES SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING TENDERING THEIR SECURITIES. The Offer to Purchase, the related Letter of Transmittal and certain other tender offer documents, as well as the Solicitation/Recommendation Statement, will be made available to all holders of LDR common stock at no expense to them. The tender offer materials and the Solicitation/Recommendation Statement will be made available for free at the SEC’s website at www.sec.gov. Additional copies may be obtained (when available) for free by contacting Zimmer Biomet or LDR. Copies of the documents filed with the SEC by LDR will be available free of charge on LDR’s website at www.ldr.com or by contacting LDR’s Investor Relations Department at (512) 344-3408. Copies of the documents filed with the SEC by Zimmer Biomet will be available free of charge

3

on Zimmer Biomet’s website at www.zimmerbiomet.com or by contacting Zimmer Biomet’s Investor Relations Department at (574) 267-6131. In addition to the Offer to Purchase, the related Letter of Transmittal and certain other tender offer documents, as well as the Solicitation/Recommendation Statement, Zimmer Biomet and LDR each file annual, quarterly and current reports and other information with the SEC. You may read and copy any reports or other information filed by Zimmer Biomet or LDR at the SEC public reference room at 100 F Street, N.E., Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for further information on the public reference room. Zimmer Biomet’s and LDR’s filings with the SEC are also available to the public from commercial document-retrieval services and at the website maintained by the SEC at www.sec.gov.

4

EX-99.4

Exhibit 99.4

June 7, 2016

Dear Valued LDR Product Designer or Consultant,

Today is an exciting day for LDR. This morning, it was announced that Zimmer Biomet will be acquiring LDR and merging it with its existing spine business. The transaction is expected to close in the third quarter of 2016, subject to the satisfaction of customary closing conditions. Until then, LDR and Zimmer Biomet will remain independent companies and it will be business as usual.

As you may know, Zimmer Biomet is a global leader in musculoskeletal healthcare committed to helping people live better lives. This transaction will combine LDR’s innovative and highly differentiated products with the broad portfolio of spinal solutions offered by Zimmer Biomet.

The benefits for you are clear. Following the close of the transaction, the combined company will have a comprehensive Spinal technology portfolio consisting of differentiated fusion and market-leading non-fusion devices that will enable us to partner with you across a broad spectrum of patient care. The combined business will maintain an expansive global distribution channel that consists of a hybrid network of direct and independent distributors in both the US and key international markets. In turn, we expect that you will enjoy complete access to an unparalleled portfolio of technologies through the LDR and Zimmer Biomet sales professionals you already know and trust.

As a Product Developer or Consultant for LDR, we want you to know that your contract remains in place and will be honored.

We believe that the combination will create a spine company with scale, talent and the technology portfolio to become a leader in the global spine market and continue to be the partner of choice for surgeons who are creating the spine technologies of the future.

Please continue to engage with your usual points of contact in the normal course of business, and feel free to reach out to your LDR representative with any questions. We will continue to deliver the same level of service and support that you have come to appreciate from LDR.

Our relationship with you is important to our continued success. We appreciate your business, loyalty and support, and are excited about this opportunity to deepen our ability to serve you in our combined efforts to positively change the lives of your patients.

Best regards,

Christophe Lavigne

President and CEO

LDR

1

Cautionary Statement Regarding Forward-Looking Statements

This communication contains forward-looking information related to Zimmer Biomet, LDR and the acquisition of LDR by Zimmer Biomet that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. All statements other than statements of historical fact are, or may be deemed to be, forward-looking statements. In some cases, forward-looking statements can be identified by the use of forward-looking terms such as “anticipate,” “estimate,” “believe,” “continue,” “could,” “intend,” “may,” “plan,” “potential,” “predict,” “should,” “will,” “expect,” “objective,” “projection,” “forecast,” “goal,” “guidance,” “outlook,” “effort,” “target”, “would” or the negative of these terms or other comparable terms. Forward-looking statements in this communication include, among other things, statements about the potential benefits of the proposed acquisition; anticipated accretion and growth rates; Zimmer Biomet’s and LDR’s plans, objectives, expectations and intentions; the financial condition, results of operations and businesses of Zimmer Biomet and LDR; and the anticipated timing of closing of the acquisition. These forward-looking statements are based on certain assumptions and analyses made by us in light of our experience and our perception of historical trends, current conditions and expected future developments, as well as other factors we believe are appropriate in the circumstances. These forward-looking statements also are based on the current expectations and beliefs of the respective managements of Zimmer Biomet and LDR and are subject to certain known and unknown risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Risks and uncertainties include, among other things, risks related to the satisfaction of the conditions to closing the acquisition (including the failure to obtain necessary regulatory approvals) in the anticipated timeframe or at all, including uncertainties as to how many of LDR’s stockholders will tender their shares of LDR common stock in the tender offer and the possibility that the acquisition does not close; risks related to the ability to realize the anticipated benefits of the acquisition, including the possibility that the expected benefits from the proposed acquisition will not be realized or will not be realized within the expected time period; the risk that the businesses will not be integrated successfully; disruption from the transaction making it more difficult to maintain business and operational relationships; negative effects of this announcement or the consummation of the proposed acquisition on the market price of Zimmer Biomet common stock and on Zimmer Biomet’s operating results; significant transaction costs; unknown liabilities; the risk of litigation and/or regulatory actions related to the proposed acquisition; other business effects, including the effects of industry, market, economic, political or regulatory conditions; future exchange rates and interest rates; changes in tax and other laws, regulations and policies; future business combinations or disposals; the uncertainties inherent in research and development; and competitive developments. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Zimmer Biomet and LDR undertake no obligation to update any of these forward-looking statements as the result of new information or to reflect events or circumstances after the date of this communication or to reflect actual outcomes. A further description of risks and uncertainties relating to Zimmer Biomet and LDR can be found in their respective Annual Reports on Form 10-K for the fiscal year ended December 31, 2015 and in their subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission (the “SEC”) and available at www.sec.gov.

2

Additional Information and Where to Find It

The tender offer referenced in this communication has not yet commenced. This announcement is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell any shares of LDR common stock or any other securities, nor is it a substitute for the tender offer materials that Zimmer Biomet and its indirect subsidiary, LH Merger Sub, Inc., will file with the SEC. The solicitation and offer to purchase LDR common stock will only be made pursuant to an Offer to Purchase, a related letter of transmittal and certain other tender offer documents. At the time the tender offer is commenced, Zimmer Biomet and LH Merger Sub will file a tender offer statement on Schedule TO, including an Offer to Purchase, a related letter of transmittal and certain other tender offer documents, and LDR will file a Solicitation/Recommendation Statement on Schedule 14D-9, with the SEC, each with respect to the tender offer. THE TENDER OFFER STATEMENT (INCLUDING THE OFFER TO PURCHASE, THE RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER TENDER OFFER DOCUMENTS) AND THE SOLICITATION/RECOMMENDATION STATEMENT WILL CONTAIN IMPORTANT INFORMATION. LDR STOCKHOLDERS ARE URGED TO READ THE TENDER OFFER STATEMENT AND SOLICITATION/ RECOMMENDATION STATEMENT, AS THEY MAY BE AMENDED FROM TIME TO TIME, AS WELL AS ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC, WHEN THEY BECOME AVAILABLE, CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION THAT HOLDERS OF LDR SECURITIES SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING TENDERING THEIR SECURITIES. The Offer to Purchase, the related Letter of Transmittal and certain other tender offer documents, as well as the Solicitation/Recommendation Statement, will be made available to all holders of LDR common stock at no expense to them. The tender offer materials and the Solicitation/Recommendation Statement will be made available for free at the SEC’s website at www.sec.gov. Additional copies may be obtained (when available) for free by contacting Zimmer Biomet or LDR. Copies of the documents filed with the SEC by LDR will be available free of charge on LDR’s website at www.ldr.com or by contacting LDR’s Investor Relations Department at (512) 344-3408. Copies of the documents filed with the SEC by Zimmer Biomet will be available free of charge on Zimmer Biomet’s website at www.zimmerbiomet.com or by contacting Zimmer Biomet’s Investor Relations Department at (574) 267-6131. In addition to the Offer to Purchase, the related Letter of Transmittal and certain other tender offer documents, as well as the Solicitation/Recommendation Statement, Zimmer Biomet and LDR each file annual, quarterly and current reports and other information with the SEC. You may read and copy any reports or other information filed by Zimmer Biomet or LDR at the SEC public reference room at 100 F Street, N.E., Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for further information on the public reference room. Zimmer Biomet’s and LDR’s filings with the SEC are also available to the public from commercial document-retrieval services and at the website maintained by the SEC at www.sec.gov.

3

EX-99.5

Exhibit 99.5

                

345 E. Main St.

Warsaw, IN 46580

www.zimmerbiomet.com

Contacts:
Media	Investors
Monica Kendrick	Robert J. Marshall Jr.
574-372-4989	574-371-8042
monica.kendrick@zimmerbiomet.com	robert.marshall@zimmerbiomet.com
	Barbara Goslee
	574-371-9449
	barb.goslee@zimmerbiomet.com

ZIMMER BIOMET TO ACQUIRE LDR TO

ENHANCE INNOVATION AND GROWTH OF SPINE BUSINESS

• Significantly Expands Portfolio of Innovative Solutions for $10 Billion Spine Market

• Positions Company to Capitalize on Faster Growing Spine Segments, including Cervical Disc Replacement

• Companies to Host Conference Call at 8:00 AM ET

(WARSAW, IN and AUSTIN, TX) June 7, 2016 – Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) (Zimmer Biomet or the Company), a global leader in musculoskeletal healthcare, and LDR Holding Corporation (NASDAQ: LDRH) (LDR), a global medical device company focused on designing and commercializing novel and proprietary surgical technologies for the treatment of patients suffering from spine disorders, today announced that both Boards of Directors have approved a definitive agreement under which Zimmer Biomet will commence a tender offer to acquire all of the outstanding shares of LDR for $37.00 per share in cash, which implies a transaction value of approximately $1.0 billion. The transaction is subject to customary closing conditions and is expected to close in the third quarter of 2016.

Founded in France in 2000, LDR designs and commercializes innovative technologies making surgical procedures easier to perform and providing improved clinical outcomes in the treatment of spine disorders. The addition of LDR will bolster Zimmer Biomet’s presence in the global Spine market and

provide the Company with an immediate and a leading position in the fast growing cervical disc replacement (CDR) and MIS segments. The combination is expected to meaningfully accelerate the growth of Zimmer Biomet’s Spine business through the incremental revenues associated with entry into the cervical disc replacement market and cross-portfolio selling opportunities to both Zimmer Biomet and LDR customer bases.

Zimmer Biomet also expects the transaction to accelerate the future growth of its overall business. With respect to 2016, the Company reiterates its previously provided revenue guidance, an increase of 2.0% to 3.0% as compared to adjusted pro forma full year 2015 on a constant currency basis. The Company will update its revenue guidance to reflect this transaction at or about the time of closing. Zimmer Biomet is also reiterating its 2016 adjusted diluted EPS guidance of $7.85 - $8.00. The transaction is expected to be neutral to adjusted diluted EPS in 2017 and accretive thereafter.

“This highly strategic and complementary transaction will enhance Zimmer Biomet’s innovation leadership in musculoskeletal healthcare by adding a premier spine platform to our portfolio of solutions,” said David Dvorak, President and CEO of Zimmer Biomet. “This combination is consistent with our goal of driving meaningful growth across all musculoskeletal markets with innovative products, technologies and services that enhance patient outcomes. The talented LDR team uniquely shares our deeply held commitment to innovating in a manner that restores mobility and alleviates pain for patients around the world, and we look forward to welcoming them to Zimmer Biomet. We are confident that the combination of Zimmer Biomet’s Spine division and LDR will create a Spine company with the scale, talent and technology portfolio to become a leader in the $10 billion global Spine market.”

Christophe Lavigne, Co-Founder, Chairman, President and CEO of LDR, said, “We are delighted with this combination, which will further our commitment to improving spine care by providing greater access to our innovative product offerings for patients around the world, while offering our stockholders immediate cash value. We have great respect for the Zimmer Biomet team, who shares our passion for innovation as well as our commitment to patients and providers. We look forward to working closely with Zimmer Biomet to achieve a seamless transition and create lasting value for all of our stakeholders.”

Strategic Benefits of the Transaction

• Enhances Zimmer Biomet’s innovative product portfolio: The combination with LDR is a natural expansion of Zimmer Biomet’s Spine business. LDR’s talent, culture and track record of innovation is evidenced by its primary product offerings based on its Mobi-C^® cervical disc replacement device and MIVo™ portfolio to support lumbar and cervical fusion procedures, both of which are complementary to Zimmer Biomet’s current portfolio. Combined, Zimmer Biomet and LDR create a differentiated and comprehensive Spine portfolio, improving Zimmer Biomet’s position for sustainable growth.

• Positions Zimmer Biomet as a market leader in CDR: CDR represents the fastest growing segment within the $10 billion Spine industry. LDR’s Mobi-C CDR device has been well received in the market as the first and only device FDA approved to treat both one- and two-level adjacent damaged cervical discs. Long-term clinical studies for Mobi-C have demonstrated the efficacy of this unique technology, with Mobi-C showing superiority to fusion for two-level procedures. These excellent clinical outcomes coupled with market-leading ease of use are expected to drive further market penetration as a part of Zimmer Biomet’s Spine portfolio. Finally, the combination positions Zimmer Biomet to leverage its scale and resources to accelerate the development of the CDR market globally.

• Significant opportunity to leverage expanded commercial channel: The Company expects to capture cross-portfolio selling opportunities to both Zimmer Biomet and LDR customer bases. Zimmer Biomet anticipates enhancing LDR’s product growth and reach by capitalizing on an expanded combined distribution channel in the U.S. and key international Spine markets. The combination also will create a comprehensive Spine portfolio with innovative surgical solutions that place Zimmer Biomet in an advantaged position to compete for large hospital vendor contracts.

Financing

Zimmer Biomet plans to finance the transaction using cash balances on hand and existing availability under its revolving credit facility and expects to maintain an investment grade profile. Following consummation of the transaction, Zimmer Biomet plans to issue $750 million of senior unsecured notes, the proceeds of which will be used to repay the credit facility. Zimmer Biomet intends to maintain its previously discussed deleveraging strategy.

Organization and Leadership

Upon consummation of the transaction, LDR will be combined with Zimmer Biomet’s Spine & CMF category and will be led by Adam Johnson, Zimmer Biomet Group President, Spine, CMF and Thoracic, and Dental. Christophe Lavigne, Co-Founder, Chairman, President and CEO of LDR and Patrick Richard, Co-Founder of LDR and Executive Vice President and General Manager of LDR Médical, are committed to driving the benefits of this transaction and will remain with the Company in key leadership positions within the global Spine business. To leverage talent and product expertise from both companies, Zimmer Biomet plans to complement the Spine business headquarters in Broomfield, Colorado by maintaining a significant presence in LDR’s strong technology hubs of Austin, Texas and Troyes, France.

Transaction Structure, Approvals and Time to Closing

The transaction is structured as an all-cash tender offer for all outstanding shares of LDR common stock at a price of $37.00 per share, followed by a merger in which each share of LDR common stock that is not tendered pursuant to the tender offer would be converted into the right to receive in cash $37.00 per share.

The transaction is subject to the expiration or termination of the applicable waiting periods under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, the tender of a majority of the outstanding LDR shares in the tender offer and other customary closing conditions. The transaction is expected to close in the third quarter of 2016.

Advisors

Goldman, Sachs & Co. is acting as financial advisor to Zimmer Biomet and White & Case LLP is acting as legal advisor. BofA Merrill Lynch is acting as financial advisor to LDR and Andrews Kurth LLP is acting as legal advisor.

Conference Call

Zimmer Biomet and LDR will host a joint conference call today, Tuesday, June 7, 2016 at 8:00 AM Eastern Time to discuss the transaction. Interested parties may join the conference call by dialing 1-888-408-5523 in the United States or +1-480-629-9848 from outside of the United States. The conference identification number is 4725679. Interested parties are invited to listen to the webcast of the conference call, which can be accessed by visiting the Investor Relations section of Zimmer Biomet’s website at www.zimmerbiomet.com.

A digital recording will be available through July 5, 2016 by dialing 1-800-406-7325 in the United States and +1-303-590-3030 from outside of the United States and using the conference identification number 4725679. A webcast replay will also be available for a limited period on Zimmer Biomet’s website in the Investor Relations section.

About Zimmer Biomet

Founded in 1927 and headquartered in Warsaw, Indiana, Zimmer Biomet is a global leader in musculoskeletal healthcare. We design, manufacture and market orthopaedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants; and related surgical products.

We collaborate with healthcare professionals around the globe to advance the pace of innovation. Our products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. Together with healthcare professionals, we help millions of people live better lives.

We have operations in more than 25 countries around the world and sell products in more than 100 countries. For more information, visit www.zimmerbiomet.com or follow Zimmer Biomet on Twitter at www.twitter.com/zimmerbiomet.

About LDR

LDR is a global medical device company focused on designing and commercializing novel and proprietary surgical technologies for the treatment of patients suffering from spine disorders. LDR’s primary products are the Mobi-C^® cervical disc replacement device and MIVo™ portfolio of products which include a range of devices to support lumbar and cervical fusion procedures. The Mobi-C^® and MIVo™ platforms are designed to enable products that are less invasive, provide greater intra-operative flexibility, offer simplified surgical techniques and promote improved clinical outcomes for patients as compared to existing alternatives. In August 2013, LDR received approval from the U.S. Food and Drug Administration (FDA) for the Mobi-C^® cervical disc replacement device, the first and only cervical disc replacement device to receive FDA approval to treat both one-level and two-level cervical disc disease. For more information regarding LDR, visit www.ldr.com.

Cautionary Statement Regarding Forward-Looking Statements

This release contains forward-looking information related to Zimmer Biomet, LDR and the acquisition of LDR by Zimmer Biomet that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. All statements other than statements of historical fact are, or may be deemed to be, forward-looking statements. In some cases, forward-looking statements can be identified by the use of forward-looking terms such as “anticipate,” “estimate,” “believe,” “continue,” “could,” “intend,” “may,” “plan,” “potential,” “predict,” “should,” “will,” “expect,” “are confident that,” “objective,” “projection,” “forecast,” “goal,” “guidance,” “outlook,” “effort,” “target,” “would” or the negative of these terms or other comparable terms. Forward-looking statements in this release include, among other things, statements about the potential benefits of the proposed acquisition; anticipated accretion and growth rates; Zimmer Biomet’s and LDR’s plans, objectives, expectations and intentions; the financial condition, results of operations and businesses of Zimmer Biomet and LDR; and the anticipated timing of closing of the acquisition. These forward-looking statements are based on certain assumptions and analyses made by us in light of our experience and our perception of historical trends, current conditions and expected future developments, as well as other factors we believe are appropriate in the circumstances. These forward-looking statements also are based on the current expectations and beliefs of the respective managements of Zimmer Biomet and LDR and are subject to certain known and unknown risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Risks and uncertainties include, among other things, risks related to the satisfaction of the conditions to closing the acquisition (including the failure to obtain necessary regulatory approvals) in the anticipated timeframe or at all, including uncertainties as to how many of LDR’s stockholders will tender their shares of LDR common stock in the tender offer and the possibility that the acquisition does not close; risks related to the ability to realize the anticipated benefits of the acquisition, including the possibility that the expected benefits from the proposed acquisition will not be realized or will not be realized within the expected time period; the risk that the businesses will not be integrated successfully; disruption from the transaction making it more difficult to maintain business and operational relationships; negative effects of this announcement or the consummation of the proposed acquisition on the market price of Zimmer Biomet common stock and on Zimmer Biomet’s operating results; significant transaction costs; unknown liabilities; the risk of litigation and/or regulatory actions related to the proposed acquisition; other business effects, including the effects of industry, market, economic, political or regulatory conditions; future exchange rates and interest rates; changes in tax and other laws, regulations and policies; future business combinations or disposals; the uncertainties inherent in research and development; and competitive developments. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Zimmer Biomet and LDR undertake no obligation to update any of these forward-looking statements as the result of new information or to reflect events or circumstances after the date of this communication or to reflect actual outcomes. A further description of risks and uncertainties relating to Zimmer Biomet and LDR can be found in their respective Annual Reports on Form 10-K for the fiscal year ended December 31, 2015 and in their subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission (the “SEC”) and available at www.sec.gov.

Additional Information and Where to Find It

The tender offer referenced in this press release has not yet commenced. This announcement is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell any shares of LDR common stock or any other securities, nor is it a substitute for the tender offer materials that Zimmer Biomet and its indirect subsidiary, LH Merger Sub, Inc., will file with the SEC. The solicitation and offer to purchase LDR common stock will only be made pursuant to an Offer to Purchase, a related letter of transmittal and certain other tender offer documents. At the time the tender offer is commenced, Zimmer Biomet and LH Merger Sub will file a tender offer statement on Schedule TO, including an Offer to Purchase, a related letter of transmittal and certain other tender offer documents, and LDR will file a Solicitation/Recommendation Statement on Schedule 14D-9, with the SEC, each with respect to the tender offer. THE TENDER OFFER STATEMENT (INCLUDING THE OFFER TO PURCHASE, THE RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER TENDER OFFER DOCUMENTS) AND THE SOLICITATION/RECOMMENDATION STATEMENT WILL CONTAIN IMPORTANT INFORMATION. LDR STOCKHOLDERS ARE URGED TO READ THE TENDER OFFER STATEMENT AND SOLICITATION/ RECOMMENDATION STATEMENT, AS THEY MAY BE AMENDED FROM TIME TO TIME, AS WELL AS ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC, WHEN THEY BECOME AVAILABLE, CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION THAT HOLDERS OF LDR SECURITIES SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING TENDERING THEIR SECURITIES. The Offer to Purchase, the related Letter of Transmittal and certain other tender offer documents, as well as the Solicitation/Recommendation Statement, will be made available to all holders of LDR common stock at no expense to them. The tender offer materials and the Solicitation/Recommendation Statement will be made available for free at the SEC’s website at www.sec.gov. Additional copies may be obtained (when available) for free by contacting Zimmer Biomet or LDR. Copies of the documents filed with the SEC by LDR will be available free of charge on LDR’s website at www.ldr.com. Copies of the documents filed with the SEC by Zimmer Biomet will be available free of charge on Zimmer Biomet’s website at www.zimmerbiomet.com. In addition to the Offer to Purchase, the related Letter of Transmittal and certain other tender offer documents, as well as the Solicitation/Recommendation Statement, Zimmer Biomet and LDR each file annual, quarterly and current reports and other information with the SEC. You may read and copy any reports or other information filed by Zimmer Biomet or LDR at the SEC public reference room at 100 F Street, N.E., Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for further information on the public reference room. Zimmer Biomet’s and LDR’s filings with the SEC are also available to the public from commercial document-retrieval services and at the website maintained by the SEC at www.sec.gov.

EX-99.6

Zimmer Biomet Announces Agreement to Acquire LDR David Dvorak President and CEO Christophe Lavigne LDR Co-Founder, Chairman, President and CEO Dan Florin SVP and CFO Adam Johnson Group President, Spine, CMF and Thoracic, and Dental June 7, 2016 Exhibit 99.6

Cautionary Statement Regarding Forward-Looking Statements This communication contains forward-looking information related to Zimmer Biomet, LDR and the acquisition of LDR by Zimmer Biomet that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. All statements other than statements of historical fact are, or may be deemed to be, forward-looking statements. In some cases, forward-looking statements can be identified by the use of forward-looking terms such as “anticipate,” “estimate,” “believe,” “continue,” “could,” “intend,” “may,” “plan,” “potential,” “predict,” “should,” “will,” “expect,” “objective,” “projection,” “forecast,” “goal,” “guidance,” “outlook,” “effort,” “target,” “would” or the negative of these terms or other comparable terms. Forward-looking statements in this release include, among other things, statements about the potential benefits of the proposed acquisition; anticipated accretion and growth rates; Zimmer Biomet's and LDR's plans, objectives, expectations and intentions; the financial condition, results of operations and businesses of Zimmer Biomet and LDR; and the anticipated timing of closing of the acquisition. These forward-looking statements are based on certain assumptions and analyses made by us in light of our experience and our perception of historical trends, current conditions and expected future developments, as well as other factors we believe are appropriate in the circumstances. These forward-looking statements also are based on the current expectations and beliefs of the respective managements of Zimmer Biomet and LDR and are subject to certain known and unknown risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Risks and uncertainties include, among other things, risks related to the satisfaction of the conditions to closing the acquisition (including the failure to obtain necessary regulatory approvals) in the anticipated timeframe or at all, including uncertainties as to how many of LDR's stockholders will tender their shares of LDR common stock in the tender offer and the possibility that the acquisition does not close; risks related to the ability to realize the anticipated benefits of the acquisition, including the possibility that the expected benefits from the proposed acquisition will not be realized or will not be realized within the expected time period; the risk that the businesses will not be integrated successfully; disruption from the transaction making it more difficult to maintain business and operational relationships; negative effects of this announcement or the consummation of the proposed acquisition on the market price of Zimmer Biomet common stock and on Zimmer Biomet's operating results; significant transaction costs; unknown liabilities; the risk of litigation and/or regulatory actions related to the proposed acquisition; other business effects, including the effects of industry, market, economic, political or regulatory conditions; future exchange rates and interest rates; changes in tax and other laws, regulations and policies; future business combinations or disposals; the uncertainties inherent in research and development; and competitive developments. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Zimmer Biomet and LDR undertake no obligation to update any of these forward-looking statements as the result of new information or to reflect events or circumstances after the date of this communication or to reflect actual outcomes. A further description of risks and uncertainties relating to Zimmer Biomet and LDR can be found in their respective Annual Reports on Form 10-K for the fiscal year ended December 31, 2015 and in their subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission (the “SEC”) and available at www.sec.gov. Additional Information and Where to Find It The tender offer referenced in this communication has not yet commenced. This announcement is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell any shares of LDR common stock or any other securities, nor is it a substitute for the tender offer materials that Zimmer Biomet and its indirect subsidiary, LH Merger Sub, Inc., will file with the SEC. The solicitation and offer to purchase LDR common stock will only be made pursuant to an Offer to Purchase, a related letter of transmittal and certain other tender offer documents. At the time the tender offer is commenced, Zimmer Biomet and LH Merger Sub will file a tender offer statement on Schedule TO, including an Offer to Purchase, a related letter of transmittal and certain other tender offer documents, and LDR will file a Solicitation/Recommendation Statement on Schedule 14D-9, with the SEC, each with respect to the tender offer. THE TENDER OFFER STATEMENT (INCLUDING THE OFFER TO PURCHASE, THE RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER TENDER OFFER DOCUMENTS) AND THE SOLICITATION/RECOMMENDATION STATEMENT WILL CONTAIN IMPORTANT INFORMATION. LDR STOCKHOLDERS ARE URGED TO READ THE TENDER OFFER STATEMENT AND SOLICITATION/RECOMMENDATION STATEMENT, AS THEY MAY BE AMENDED FROM TIME TO TIME, AS WELL AS ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC, WHEN THEY BECOME AVAILABLE, CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION THAT HOLDERS OF LDR SECURITIES SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING TENDERING THEIR SECURITIES. The Offer to Purchase, the related Letter of Transmittal and certain other tender offer documents, as well as the Solicitation/Recommendation Statement, will be made available to all holders of LDR common stock at no expense to them. The tender offer materials and the Solicitation/Recommendation Statement will be made available for free at the SEC's website at www.sec.gov. Additional copies may be obtained (when available) for free by contacting Zimmer Biomet or LDR. Copies of the documents filed with the SEC by LDR will be available free of charge on LDR's website at www.ldr.com. Copies of the documents filed with the SEC by Zimmer Biomet will be available free of charge on Zimmer Biomet's website at www.zimmerbiomet.com. In addition to the Offer to Purchase, the related Letter of Transmittal and certain other tender offer documents, as well as the Solicitation/Recommendation Statement, Zimmer Biomet and LDR each file annual, quarterly and current reports and other information with the SEC. You may read and copy any reports or other information filed by Zimmer Biomet or LDR at the SEC public reference room at 100 F Street, N.E., Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for further information on the public reference room. Zimmer Biomet's and LDR's filings with the SEC are also available to the public from commercial document-retrieval services and at the website maintained by the SEC at www.sec.gov.

Spine Market 3 Agenda Transaction Summary 4 Transaction Overview 1 Overview of LDR 2

Highly Complementary Strategic Transaction Highly strategic and complementary acquisition that strengthens one of Zimmer Biomet’s key franchises: Spine Accelerated growth in the $10 billion Spine market, enabling Zimmer Biomet to gain a leading position in its fastest growing segment Creates comprehensive Spine portfolio with innovative surgical solutions that place Zimmer Biomet in an advantaged position to compete for large hospital vendor contracts Significant global opportunity for LDR products through Zimmer Biomet’s larger, global presence in both U.S. and key international markets Christophe Lavigne, Co-Founder, Chairman, President and CEO of LDR and Patrick Richard, Co-Founder of LDR and Executive Vice President and General Manager of LDR Médical, will remain with the Company in key leadership positions

Purchasing LDR for $37.00 per share in cash via tender offer Total purchase price ~$1.0 billion Price ~5.5x 2016 revenue (midpoint of LDR management full-year revenue guidance) Valuation Expected close in third quarter of 2016 Subject to customary closing conditions Timing Adjusted diluted EPS 2017: Neutral Adjusted diluted EPS 2018 and Beyond: Accretive ZBH Accretion Expect to maintain investment grade debt rating and prior 2017/2018 leverage targets ZBH Balance Sheet Transaction Overview Integration Proven track-record of successfully integrating acquisitions LDR Transaction Overview

Overall Trial Success Through 5 Years Focus on Spine Two Exclusive Technology Platforms ü Mobi-C® ü MIVoTM Represented over 92% of Revenue in 2015 Attractive Financial Profile $164M Revenue in 2015 21% Growth CC in 2015 v 2014 83.4% Gross Margin in 2015 Geographic Mix U.S.: 81% Revenue in 2015 OUS: 19% Revenue in 2015 Operations Founded in France in 2000 Global Headquarters in Austin, TX More than 550 Employees Worldwide LDR At-A-Glance Source: LDR

Mobi-C Cervical Disc Replacement Device First and only artificial cervical disc approved in the U.S. for both one- and two-level indication U.S. Approval in August 2013 PMAs started in 2005 One of the largest prospective, randomized clinical studies ever completed in spine ~600 patients: 24 centers 11 years of clinical experience Over 40,000 implantations Over $100M cumulative revenue in U.S. since product introduction in late 2013 Five-Year Superiority Claim over Fusion for Two-Level Indication Source: LDR

Current U.S. Cervical Disc Replacement Market Opportunity Mobi-C is uniquely well-positioned to be the market leader: The first and currently only on label two-level indication Overall superiority claim for two-level application through 5 years Over 450 issued patents worldwide Simplified surgical technique Proven materials Cervical Disc penetration into the ACDF1 procedure base will continue to expand due to: Increasingly broad payer coverage Dissemination of long-term evidence Surgeon community proficiency Patient demand Source: LDR 1Anterior cervical discectomy and fusion

LDR: Revenue Through Exclusive Technology 21% CAGR – Total Revenue 129% CAGR – Mobi-C 16% Growth 2015 v 2014 (21% CC) Source: LDR ($ in millions) $

Largest musculoskeletal market: *~$10bn Fastest growing segments Cervical Disc MIS Complex Spine Market dynamics are favorable Demographics driving volume growth globally Market share shifts driven by differentiated technologies and unique products Snapshot of Today’s Spine Market Spine Market Share Source: Public filings, Zimmer Biomet management *2016 estimated market size

Comprehensive Spine Portfolio Acquisition will create a comprehensive Spine portfolio, adding high growth cervical disc replacement and zero profile fusion products Complex Spine and Biologics MIS Cervical Disc Replacement Exclusive Technology Platforms Existing Portfolio

Financial Summary Accelerates top-line growth with sustainable differentiated platform in Spine, the largest musculoskeletal market Prudent use of cash and new borrowing under revolving credit facility to fund the transaction – expect to launch debt offering in Q3 to repay credit facility Expect to maintain investment grade credit rating Reiterate 2016 pro-forma, constant currency revenue growth guidance of 2.0%-3.0% (1.0%-2.0% reported), with LDR revenue incremental Reiterate 2016 adjusted diluted EPS guidance of $7.85 - $8.00 Transaction is neutral to adjusted diluted EPS in 2017 and accretive thereafter

Transaction Summary Highly strategic and complementary acquisition that strengthens one of Zimmer Biomet’s key franchises: Spine Accelerated growth in the $10 billion Spine market, enabling Zimmer Biomet to gain a leading position in its fastest growing segment Creates comprehensive Spine portfolio with innovative surgical solutions that place Zimmer Biomet in an advantaged position to compete for large hospital vendor contracts Significant global opportunity for LDR products through Zimmer Biomet’s larger, global presence in both U.S. and key international markets Christophe Lavigne and Patrick Richard will remain with the Company in key leadership positions

Questions & Answers